• Press Release

Mount Sinai Receives Grant to Enhance Patient-Centric, Team-Based Pancreatic Cancer Care

New multidisciplinary team and center of excellence deepen commitment to this complex cancer

  • New York, NY
  • (April 19, 2022)

The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued innovation in its multidisciplinary treatment of pancreatic cancer.

The Canopy Cancer Collective partners with leading health care institutions to create new patient-centric learning health networks, connecting top medical care providers, cancer researchers, and wellness specialists to formulate and foster best practices in cancer care all while empowering patients throughout their cancer journey. Mount Sinai is the only institution in New York City to receive this prestigious grant award and is among only 14 centers nationally.

Pancreatic cancer is called the “silent killer” because symptoms do not usually appear until it has already spread to other organs, leading to low survival rates. Pancreatic cancer is a complex disease that can affect each patient in different ways, both from the effects of the cancer itself and as a consequence of therapy, especially because multimodality therapy is often required.

Because of these complexities, multidisciplinary care is essential to achieving optimal outcomes for patients, underscoring the importance of the Canopy Cancer Collective grant award as well as two other important new milestones that further streamline pancreatic cancer patients’ care at Mount Sinai. In April, Mount Sinai is launching the Center of Excellence for Pancreatic Cancer Multidisciplinary Team (Pancreas MDT) at Mount Sinai West, and The Tisch Cancer Institute is launching the Center of Excellence for Pancreatic Cancer at Mount Sinai.

“As one of the most experienced pancreatic disorders treatment programs in the United States, Mount Sinai is recognized for excellence in the management of pancreatic diseases by esteemed organizations such as the National Pancreas Foundation,” said Karyn A. Goodman, MD, MS, Professor and Vice Chair for Research and Quality in the Department of Radiation Oncology at the Icahn School of Medicine at Mount Sinai, and Associate Director for Clinical Research at The Tisch Cancer Institute at Mount Sinai. “The Canopy Cancer Collective grant award in combination with our Pancreatic Cancer Multidisciplinary Team and our Center of Excellence deepens our commitment to provide seamless patient-centric treatment of pancreatic cancer. We will provide the most comprehensive and compassionate care through a multidisciplinary pancreatic cancer team providing the highest-quality diagnostic evaluation, treatment, and care and access to innovative therapies through clinical trials.”

The Pancreas MDT will have a team of specialists who are national leaders in the field who will provide the highest-quality diagnostic tools, treatment, and care for patients with pancreatic cancer. The team includes experts from gastroenterology, surgery, medical oncology, radiation oncology, pathology, and radiology, as well as nutritionists, social workers, and genetic counselors. 

The team will deliver cutting-edge treatment for pancreatic cancer patients, informed by Mount Sinai’s extensive translational research program. In a one-day visit with the multidisciplinary team, patients will receive an individualized treatment plan that would otherwise take weeks elsewhere.

Patients will also have access to innovative therapies through clinical trials at multiple locations throughout the Health System. Patients and their family members will also receive extensive supportive care services.

The Pancreas MDT will fall under the overall umbrella of the Center of Excellence for Pancreatic Cancer at Mount Sinai, which is committed to streamlined, quality pancreatic cancer care. Dr. Goodman; Daniel Labow, MD; and Deirdre Cohen, MD, MS, will lead the Center of Excellence.

Together, they have internationally recognized expertise in radiation oncology, clinical trials, surgical oncology, and medical oncology, which will fuel the streamlined approach to team care across the health system. The Center is part of The Tisch Cancer Institute at Mount Sinai, a National Cancer Institute-designated Cancer Center. In 2021, Mount Sinai announced the establishment of the Mount Sinai Tisch Cancer Center and the construction of a new state-of-the-art cancer hospital in Manhattan thanks to a generous donation by James S. and Merryl H. Tisch.

“At the Center of Excellence for Pancreatic Cancer, we believe everyone deserves personalized and excellent care, so we develop an individualized treatment plan for our patients, using the latest technologies and advances,” said Dr. Labow, who is also Executive Vice Chair of the Department of Surgery at the Mount Sinai Health System.

Dr. Cohen, who is also Director of the Gastrointestinal Oncology Program at the Mount Sinai Health System, added, “Through this center, and our ongoing research, we will continue to make progress in the diagnosis and treatment of pancreatic cancer, keeping a patient centric focus to treat the whole person.”

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2023-2024.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.